However, as recent studies show, in CML cells resistant to tyrosine kinase inhibitors the non-canonical Wnt-pathway might interfere when the BCR-ABL-mediated mechanism is inhibited. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.